Partner Headlines - ALKS

  1. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  2. Alkermes' drug passes trial

    IBD
  3. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  4. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  5. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  6. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  7. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  8. Benzinga's Volume Movers

    Benzinga
  9. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  10. Morning Market Movers

    Benzinga
  11. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  12. Benzinga's Top Initiations

    Benzinga
  13. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  14. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  15. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  16. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  17. Stocks End Short Week With Big Losses

    IBD
  18. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  19. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  20. Ireland Home To Several Fast Growing Health Care Names

    IBD
  21. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  22. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  23. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  24. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  25. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  26. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  27. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  28. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  29. Alkermes

    IBD
  30. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  31. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  32. Alkermes

    IBD
  33. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  34. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  35. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  36. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  37. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  38. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  39. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  40. Stocks Pare Early Losses, End With Modest Declines

    IBD
  41. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  42. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  43. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  44. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  45. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  46. Dow Leads Market Higher As Volume Swells

    IBD
  47. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  48. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  49. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  50. Stocks Tumble On Disappointing Earnings Reports

    IBD
  51. Why Cisco, Google And Apple All Became Big Winners

    IBD
  52. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  53. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
  54. Alkermes In Buying Range Above Cup-Base Entry

    IBD
  55. Alkermes Writes New Prescription For Growth

    IBD
  56. Lennar, Other Homebuilders Crush Profit Estimates

    IBD
  57. Health Care Sector Wrap

    FoxBusiness
  58. UPDATE: J.P. Morgan Lowers Alkermes' PT

    Benzinga
  59. UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for ...

    Benzinga
  60. Elan

    IBD
  61. Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary ...

    Benzinga
  62. Alkermes Announces a Secondary Offering of 13,900,000 Ordinary ...

    Benzinga
  63. Market Roundup

    Benzinga
  64. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  65. Alkermes Files Resale Shelf Registration in Connection with Elan ...

    Benzinga
  66. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  67. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  68. Alkermes Inc. (ALKS) Director and CEO, Alkermes plc Richard F ...

    GuruFocus
  69. Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon ...

    Benzinga
  70. Benzinga's M&A Chatter for Monday January 30, 2012

    Benzinga
  71. Benzinga's Top Pre-Market Gainers

    Benzinga
  72. UPDATE: FDA Approves BYDUREON, for Type 2 Diabetes

    Benzinga
  73. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  74. Benzinga's Volume Gainers

    Benzinga
  75. CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous ...

    Benzinga
  76. Feuerstein: Alkermes CEO says Bydureon Drug will be Approved ...

    Benzinga
  77. Top-Performing Fund Managers Tap Retail, Food Stocks

    IBD
  78. Positive Data Lifts Stocks in Early Trading

    MarketIntelligenceCenter
  79. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
Trading Center